October 13, 2018

MBRX: Moleculin Biotech, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	7.96
Enterprise Value ($M)	-1.45
Book Value ($M)	7.48
Book Value / Share	2.49
Price / Book	1.06
NCAV ($M)	-4.31
NCAV / Share	-1.44
Price / NCAV	-1.85

Profitability (mra)
Return on Invested Capital (ROIC)	-3.78
Return on Assets (ROA)	-0.76
Return on Equity (ROE)	-0.86

Liquidity (mrq)
Quick Ratio	2.08
Current Ratio	2.08

Balance Sheet (mrq) ($M)
Current Assets	11.61
Assets	23.39
Liabilities	15.91
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
11-14	13G/A	Armistice Capital, Llc	9.99	-90.92

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-11-08	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-26	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-03-22	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-26	18,043	51,078	35.32
2024-11-25	2,723	28,298	9.62
2024-11-22	8,349	30,668	27.22
2024-11-21	1,641	17,096	9.60
(click for more detail)

Similar Companies
LSTA – Lisata Therapeutics, Inc.	LTRN – Lantern Pharma Inc.
MBIO – Mustang Bio, Inc.	ME – 23andMe Holding Co.
MEIP – MEI Pharma, Inc.

Financial data and stock pages provided by
Fintel.io

Finpedia: Moleculin Biotech

Related